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Background: The aim of this study was to determine the maximum
tolerated dose (MTD), dose limiting toxicities (DLTs), and determine
the phase II dose for the combination of irinotecan-carboplatin-pacli-
taxel given as induction chemotherapy and with concomitant chest
radiotherapy for patients with Stage III non-small cell lung cancer.
Methods: Patients with Cancer and Leukemia Group B performance
status of 0 to 2, stage IIIA and IIIB NSCLC patients with resectable
or unresectable disease were treated with induction chemotherapy
(irinotecan 100 mg/m2, carboplatin AUC 5, and paclitaxel 175
mg/m2 days 1 and 22) followed by concomitant chemotherapy
(irinotecan, carboplatin, and paclitaxel) and chest radiotherapy (66
Gy for unresectable and 50 Gy for resectable disease) beginning on
week 7. The primary objective was to escalate the dose of irinotecan
during chemoradiation in sequential cohorts to determine the DLT
and MTD of the regimen.
Results: Thirty-eight patients were enrolled (median age 63 years,
57% male, 41% performance status 0, 30% resectable). Induction
chemotherapy was tolerable and active (response rate 26%; stable
disease 60%). Eight patients did not receive concurrent chemora-
diotherapy because of progressive disease (5), death (1), hypersen-
sitivity reaction to paclitaxel (1), and withdrawal of consent (1).
Twenty-nine patients received concurrent chemoradiotherapy. The
concomitant administration of chest radiotherapy with weekly iri-
notecan, carboplatin, and paclitaxel was not feasible at the first,
second, and third dose levels. DLT was failure to achieve recovery
to  grade 1 absolute neutrophil count by the day of scheduled
chemotherapy administration. Dose de-escalation to irinotecan 30
mg/m2, paclitaxel 40 mg/m2 (with omission of carboplatin) deliv-
ered on weeks 2, 3, 5, and 6 of radiotherapy was the MTD. After
induction chemotherapy, partial responses, stable disease, and pro-
gressive disease was observed in 26%, 60%, and 14% of patients,
respectively. After chemoradiotherapy, partial responses were at-
tained in 16 (55%) patients, whereas 12 patients (41%) attained
disease stabilization. Median overall survival was 21 months for the
entire cohort. Resectable patients had a median survival of 24
months, whereas unresectable patients had a median survival of 19
months. Differences in overall and progression-free survival rates
between resectable and unresectable patients was not statistically
significant (p  0.52 and p  0.90, respectively).
Discussion: Carboplatin, paclitaxel, and irinotecan with concurrent
chemoradiotherapy was poorly tolerated as a result of neutropenia.
Although dose de-escalation was required for delivery of the regi-
men, the response rates and survival outcomes were comparable to
other similar regimens.
Key Words: Non-small cell lung cancer, Irinotecan, Radiation
therapy, Multimodality therapy.
(J Thorac Oncol. 2008;3: 59–67)
Lung cancer remains the most common cause of cancerdeath in the United States.1 Approximately 20 to 30% of
patients with non-small cell lung cancer (NSCLC) present
with stage III disease. Much progress has been made in the
treatment of stage III NSCLC over the past several decades
with the development of multimodality therapy. Currently,
concurrent chemoradiotherapy is the most effective manage-
ment for inoperable Stage III NSCLC resulting in long-term
overall survival in the range of 15 to 25%.2–6 Nevertheless,
despite these advances in therapy, most patients succumb to
the disease as a result of either locoregional or distant failure.
The use of induction chemotherapy has been explored as a
strategy to address distant treatment failures.7–10 Although the
response rate to induction chemotherapy is approximately 30
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to 40%, long-term survival remains unchanged.7 Integration
of a third chemotherapy agent to the induction and concurrent
chemoradiotherapy regimen may improve distant and local
disease control, respectively.
Irinotecan, a derivative from the Camptotheca acumi-
nata tree, inhibits DNA and RNA synthesis through DNA
topoisomerase I inhibition.11 Preclinical data suggests syner-
gistic relationships between the combination of irinotecan,
carboplatin, and paclitaxel.12–14 Furthermore, irinotecan po-
tentiates the cytotoxic effects of radiation therapy in tumor
cell lines and tumor xenografts.15–18 The active metabolite of
irinotecan, SN38, increases the proportion of cells in the
G2-M and M phase. These cell cycle phases are the most
sensitive to radiation injury.16
Doublet19,20 and triplet21,22 irinotecan combinations
were shown to be well tolerated and efficacious in metastatic
NSCLC. Doses of irinotecan 100 mg/m2, paclitaxel 175
mg/m2, and carboplatin AUC 5 every 3 weeks can be safely
administered together.21 This regimen achieved a response
rate of 32% with a median time to progression of 5 months in
patients with metastatic NSCLC.22 Irinotecan has also been
combined with radiation therapy. Phase I studies determined
the recommended Phase II dose of irinotecan to be 40 to 45
mg/m2/wk with thoracic radiation therapy.23,24 Other investi-
gators have combined irinotecan and platinum analogs during
thoracic radiation therapy.25,26 In patients with unresectable
stage III NSCLC, induction chemotherapy with carboplatin,
paclitaxel, and irinotecan followed by concurrent carboplatin,
paclitaxel, and radiotherapy was well tolerated and achieved
a 1 year overall survival of 73%.27
Based on the scientifically sound preclinical and prom-
ising clinical data of integrating irinotecan into existing
NSCLC regimens, we conceived this phase I study in 1999 to
evaluate the addition of irinotecan to carboplatin and pacli-
taxel during induction chemotherapy and during concurrent
chemoradiotherapy. This phase I study aimed to determine
the dose limiting toxicity (DLT) and the maximum tolerated
dose (MTD) of irinotecan that could be administered in
combination with paclitaxel, carboplatin with concomitant
thoracic radiotherapy for stage III NSCLC. Here we report
the results of our phase I trial with mature survival data.
METHODS
Patient Selection
Eligibility criteria included previously untreated, histolog-
ically or cytologically confirmed stage IIIA or IIIB NSCLC
(1997 American Joint Committee on Cancer). Patients were
excluded if they had a pleural effusion involving more than one
third of the respective hemithorax or was cytologically positive.
Additional eligibility requirements included Cancer and Leuke-
mia Group B (CALGB) performance status (PS) of 0, 1, or 2 and
measurable or evaluable disease.
Pretreatment staging evaluation included a complete
history and physical examination, complete blood count, and
complete metabolic panel. Prestudy radiographs included
posterior-anterior (PA) and lateral chest x-rays, a chest com-
puted tomography (CT) scan including the liver and adrenal
glands, a head CT, and a bone scan. Surgical resectability was
determined by thoracic surgeons before registration.
Laboratory measures required at study entry included
white blood count 3500/l; absolute neutrophil count
(ANC) 1500/l; hemoglobin 10 g/dl; platelet count
100,000/l; blood urea nitrogen 1.5 times the institu-
tional limit of normal; creatinine 1.5mg/dl or creatinine
clearance 50 ml/min[Cockcroft]; bilirubin 1.5 times
the institutional limit of normal; and serum glutamic-
oxaloacetic transaminase 2 times the institutional limit
of normal.
Patients were excluded if they had a serious medical or
psychiatric illness which might complicate or interfere with
chemotherapy or radiation administration, were taking phe-
nytoin, phenobarbital, or other antiepileptic prophylaxis, or
were pregnant or lactating. Patients could not have any
additional active malignancy or malignancy within 3 years
excluding nonmelanoma skin cancer. Patients were not per-
mitted to have undergone previous chemotherapy or radio-
therapy for NSCLC. Patients with a known history of Gilbert
syndrome were excluded because these individuals may ex-
perience excessive irinotecan-induced toxicity.
All patients gave written, witnessed, and informed
consent before study entry.
Treatment
Induction Chemotherapy
Induction chemotherapy consisted of two 21-day cycles
of irinotecan, carboplatin, and paclitaxel (Figure 1). All three
agents were given on days 1 and 22 as described by Socinski
et al. Irinotecan was given at 100 mg/m2 intravenously over
90 minutes. Carboplatin was dosed at a target AUC of 5, and
was given intravenously over 60 minutes. Paclitaxel was
given at 175 mg/m2 intravenously over 60 minutes. Premed-
ication before the administration of the chemotherapy con-
FIGURE 1. Treatment shema for dose level O.
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sisted of diphenhydramine 50 mg IV with famotidine 20 mg
IV 30 minutes before paclitaxel. In addition, dexamethasone
20 mg IV and ondansetron 24 mg was given orally 30
minutes before the irinotecan. Routine prophylactic use of
colony-stimulating factor was not allowed. Patients under-
went response assessment after 2 cycles of induction chemo-
therapy and those with documented disease progression dis-
continued protocol therapy.
Concomitant Chemoradiotherapy
Concomitant therapy began on week 7 of protocol treat-
ment. This phase I cohort study planned escalating doses of
irinotecan and fixed doses of carboplatin and paclitaxel with
concurrent chest radiotherapy. The initial schedule of drug
administration (dose level 0) consisted of weekly doses of
irinotecan 30 mg/m2, carboplatin with AUC of 2, and paclitaxel
45 mg/m2 (Figure 1 and Table 3). Because dose level 0 was not
feasible because of dose limiting toxicities, for subsequent dose
levels, carboplatin was omitted and chemotherapy paclitaxel and
irinotecan were administered at a reduced dose and frequency as
noted in the de-escalation schedule. Dose level 1 consisted of
weekly infusions of irinotecan 30 mg/m2 and paclitaxel 45
mg/m2. Dose level 2 consisted of weekly doses of irinotecan
30 mg/m2 and paclitaxel 40 mg/m2. Dose level3 consisted of
irinotecan 30 mg/m2 and paclitaxel 40 mg/m2 given on weeks 2,
3, 5, and 6.
Radiotherapy
All patients underwent CT-based treatment planning
with custom immobilization. All gross tumor and involved
lymph nodes as seen on CT or positron emission tomography
was included in the 66 Gy volume. Gross tumor was typically
expanded by 1.5 to 2 cm to create a planning target volume.
Treatment of uninvolved nodes was at the discretion of the
treating oncologist. For patients who did not undergo surgical
resection, the radiotherapy dose totaled 66 Gy in 2 Gy single
daily fractions. For patients who were to undergo surgical
resection, the radiotherapy dose totaled 50 Gy in 2 Gy single
daily fractions. Total spinal cord dosage did not exceed 46
Gy. No dose limits were placed on normal lung, bone mar-
row, or heart.
Surgical Resection
Surgical resectability was determined by a thoracic
surgeon at the time of registration. For surgically resectable
candidates, a total radiation dose not exceeding 50 Gy was
delivered, whereas for surgically unresectable candidates, a
definitive radiotherapy dose of 66 Gy was administered. If
surgical resection was feasible, patients were operated on
after completion of induction chemotherapy and concurrent
chemoradiotherapy. A CT scan was performed between week
4 and 5 of concurrent chemoradiotherapy to again determine
the feasibility of surgical resection.
For patients who achieve a significant tumor response
after induction chemotherapy, surgical resection may be con-
sidered before chemoradiotherapy, at the discretion of the
medical oncologist and thoracic surgeon. If surgical resection
was undertaken after induction chemotherapy, the chemora-
diotherapy protocol (50 Gy) was resumed within 4 weeks
after surgical resection.
Phase I Study Dose Escalation and Definition
of MTD and DLT
The objective of this phase I study was to identify the
DLTs and maximum administered dose (MAD) of irinotecan
when administered in combination with paclitaxel, carbopla-
tin, and concomitant chest radiotherapy. Toxicity was as-
sessed continually throughout protocol therapy and graded
according to the National Cancer Institute Common Termi-
nology Criteria for Adverse Events 2.0. DLT for concomitant
chemoradiotherapy was defined as any of the following which
occurred during the entire course of chemoradiotherapy: grade 4
thrombocytopenia or neutropenia, neutropenic fever, or need for
platelet transfusion; ongoing myelosuppression  grade 2 on
any subsequent chemotherapy treatment day; grade 4 esophagi-
tis; grade 4 vomiting or diarrhea despite maximal antiemetic or
antidiarrheal support; all other  grade 3 nonhematologic tox-
icities exceeding 7 days duration. Anemia, nausea, and alopecia
were not considered dose-limiting.
According to the original design, a total of three to six
patients were to be treated at any given dose of irinotecan. If
DLT occurred in zero of three patients, we proceeded to the
next dose level. If DLT occurred in one or two of three
patients, a total of up to six evaluable patients were treated at
that dose level, and if DLT occurred in two or fewer of the six
patients, we proceeded to the next dose level. If DLT oc-
curred in three of three patients, we stopped dose escalation
and declared that dose level as the MAD. There would be no
dose escalation beyond the MAD. If DLT occurred in greater
than two of six patients, we stopped dose escalation and
declared that dose level as the MAD. Doses were not esca-
lated in individual patients. The recommended phase II dose
will be one dose level below the MAD. Because dose level 0
was not feasible because of dose-limiting toxicities, the
chemotherapy doses were reduced for subsequent dose levels,
and the amended protocol stipulated dose de-escalation if
33% of patients treated at the initial dose level studied
experienced a DLT. If dose de-escalation was required, the
MTD would be defined as the highest dose level at which
33% of patients experienced DLT.
Dose Modifications
Dose modifications of irinotecan, carboplatin, and pac-
litaxel were specified for myelosupppression, nephrotoxicity,
ototoxicity, nausea/vomiting, peripheral neuropathy, diar-
rhea, hepatic toxicity, and radiotherapy-related toxicities. The
management of hematologic toxicities differed for the induc-
tion chemotherapy and concomitant chemoradiotherapy por-
tions of treatment. Management of nonhematologic toxicities
was identical for the induction chemotherapy and concomi-
tant chemoradiotherapy portions of treatment. Filgrastin sup-
port was not allowed during the induction or concomitant
chemoradiotherapy portion of treatment.
During induction chemotherapy, dose modification was
based upon the blood counts on the day of chemotherapy
treatment or observation of neutropenic fever on any day of
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the cycle. For hematologic toxicity evident on a treatment
day, the dose was modified accordingly: (1) if the ANC
was 1000 to 1500/l or platelets 50,000 to 74,000/l, then
irinotecan, carboplatin, and paclitaxel were reduced by
50%; (2) if the ANC was 1000/l or platelets 50,000/
l, then all the chemotherapy was delayed until resolution
to  grade 2, then chemotherapy was to continue at 50%
of the previous dose.
During concomitant chemoradiotherapy, for grade 4
ANC or platelets, chemotherapy and radiotherapy were de-
layed until resolution to  grade 1, and then irinotecan,
carboplatin, and paclitaxel were continued at 50% of the
previous dose. For neutropenic fever, chemotherapy and
radiotherapy were delayed until resolution to  grade 2, and
then irinotecan, carboplatin, and paclitaxel were continued at
50% of the previous dose. For grade 2 or 3 ANC or platelets,
chemotherapy was delayed until resolution to grade 1, then
irinotecan, carboplatin, and paclitaxel were continued at 75%
of the previous dose. For grade 4 mucositis, stomatitis,
esophagitis, dermatitis or other in-field radiotherapy related
toxicity during radiotherapy or on day 1 of any treatment
week, chemotherapy and radiotherapy were delayed until
resolution of toxicity to  grade 3, then irinotecan, carbo-
platin, and paclitaxel were continued at 50% of the previous
dose. If grade 4 vomiting occurred despite aggressive anti-
emetic prophylaxis, the carboplatin and irinotecan doses were
decreased by 50% for subsequent cycles. If grade 2 neuro-
toxicity developed, patients were retreated upon recovery to
grade  1 toxicity with a 25% dose reduction of carboplatin
and paclitaxel. If grade 3 neurotoxicity developed, carbopla-
tin and paclitaxel were discontinued. For all other toxici-
ties  grade 3 (except alopecia, lymphopenia, and anemia),
chemotherapy and radiation therapy was held until resolution
to  grade 1, then reinstituted, at a 25% dose reduction of
irinotecan, carboplatin, and paclitaxel.
Assessment of Response and Toxicity
Patients were assessed with regard to safety and toler-
ability using the National Cancer Institute Common Termi-
nology Criteria for Adverse Events 2.0. Tumor response was
defined using the World Health Organization Tumor Re-
sponse Criteria. Patients were to be evaluated for response 9
to 11 weeks after the initiation of therapy and then approxi-
mately 1 month after the completion of concomitant chemo-
radiotherapy or as otherwise clinically indicated.
Statistical Analysis
Response rates (complete and partial responses) were
computed and exact 95% confidence intervals (CIs) were
constructed based on the binomial distribution. Progression-
free survival (defined as the interval between the first day of
therapy and disease progression or death from any cause) and
overall survival (defined as the interval between the first day
of therapy and death from any cause) curves were estimated
for all enrolled, eligible patients using the Kaplan-Meier
method.28 CIs for the median survival times were obtained as
described in Brookmeyer and Crowley.29 Survival rates were
compared between groups using the log-rank test.
RESULTS
Patient Selection and Characteristics
Between December 1999 and November 2003, a total
of 38 patients enrolled in the study (Table 1). One patient
enrolled on the study and received the intended therapy but
on review was found to have metastatic disease at the time of
enrollment. This patient was excluded from all analyses
leaving 37 eligible patients.
There were 21 men and 16 women with a median age
of 63 years (range 42–80). Caucasians and African Ameri-
cans patients were equal in number. Thirty-three patients
(89%) had a PS of 0 or 1. The predominant histology was
adenocarcinoma with 35%, followed by undifferentiated non-
small cell 27%, squamous cell 27%, and large cell 11%.
Approximately one third of patients had Stage IIIA NSCLC.
The majority of patients did not experience weight loss before
diagnosis. Only 11% had weight loss greater than 10% of
body weight. Eleven patients (30%) were considered poten-
tially resectable at the time of registration.
TABLE 1. Patient Characteristics
Characteristic
Total enrolled 38a
Median age (range) 63 yr (42–80 yr)
Gender
Male 21 (57)
Female 16 (43)
Race
Caucasian 18 (49)
African American 18 (49)
Hispanic 1 (3)
ECOG performance status
0 15 (41)
1 18 (49)
2 4 (11)
Histology
Adenocarcinoma 13 (35)
Squamous cell 10 (27)
Large cell 4 (11)
Non-small cell 10 (27)
Stage
IIIA 13 (35)
IIIB 24 (65)
Weight loss
No weight loss 25 (68)
Less than 10% 8 (22)
Greater than 10% 4 (11)
Resectable
Yes 11 (30)
No 26 (70)
Values in parenthesis indicate percentage values.
a One patient enrolled on the study and received the intended therapy but on
retrospective review was found to have metastatic disease at the time of enrollment.
This patient was excluded from all analyses.
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Induction Chemotherapy: Toxicity and
Response
One patient developed a hypersensitivity reaction to
paclitaxel during the first cycle of induction chemotherapy
and discontinued protocol therapy. As a result, 36 patients
were considered fully assessable for safety associated with
the use of all three induction chemotherapy agents. Seventy-
one cycles of induction chemotherapy were administered.
Four patients experienced myelosuppression (one patient
with grade 3 neutropenia and three patients with grade 4) and
required dose modification of the second cycle of induction
chemotherapy.
Induction chemotherapy toxicities are listed in Table 2.
Significant toxicities for patients were mainly hematologic.
Grade 3/4 leukopenia and neutropenia occurred in four (12%)
and 17 (47%) patients, respectively. Neutropenic fever and
non-neutropenic infections each occurred in two patients
(6%). Grade 3/4 diarrhea and grade 3/4 vomiting each oc-
curred in one patient (3%). The most common nonhemato-
logic toxicity was fatigue, which occurred in 80% of patients.
Thirty-five patients were assessable for response to
induction chemotherapy. One patient developed a hypersen-
sitivity reaction to paclitaxel and was treated off protocol.
Another patient developed acute liver failure secondary to
alcohol cirrhosis after cycle 1 and did not receive further
study therapy. Partial responses were observed in nine of the
35 assessable patients (26%; 95%CI, 12%–43%). Twenty-
one (60%) had stable disease. Five patients (14%) developed
progressive disease after induction chemotherapy. Of the five
patients with progressive disease, two had local disease
progression and three developed distant metastases to the
skin, liver, and retroperitoneum, respectively. Of the two
patients with local disease progression, one patient had tumor
invasion into the heart ventricle and no further therapy was
administered, whereas another patient was taken off protocol
and given chemoradiotherapy.
Concurrent Chemotherapy and Radiotherapy
Phase I Dose Escalation and Determination of
MTD
Twenty-nine patients (22 unresectable and seven re-
sectable) received concurrent chemoradiotherapy and all
were evaluable for toxicity (Table 3). Eight patients did not
receive concurrent chemoradiotherapy because of progressive
disease (five patients), death from decompensated alcohol
cirrhosis (one patient), hypersensitivity reaction to paclitaxel
(one patient) and withdrawal of consent (one patient).
A total of 163 cycles of chemoradiotherapy were ad-
ministered and the median number of cycles per patient was
six (range 4–6). For patients with resectable tumors (n  7),
a total of 33 cycles were administered and the median number
of cycles per patient was five (range 4–5). For patients with
unresectable tumors (n  22), a total of 130 cycles were
administered and the median number of cycles per patient
was six (range 5–6).
There were no treatment-related deaths. DLT occurred
in 12 patients and failure to achieve recovery to  grade 1
ANC by the day of scheduled chemotherapy administration
was the predominant DLT occurring in 10 patients. All four
patients in the first dose level (dose level 0) experienced
DLT. Three out of six patients (50%) in dose level 1
experienced DLT. Further dose de-escalation was required
because four out of 10 patients (40%) experienced DLT in
dose level 2. DLT at dose level 2 was grade 3 pneumonia
(one patient), grade 3 angina (one patient) and failure to
achieve recovery to  grade 1 ANC by the day of scheduled
chemotherapy administration (two patients). At dose level
3, only one patient (11%) experienced DLT. Therefore, the
MAD was dose level 0, and the MTD was dose level 3.
Hematologic and nonhematologic toxicities by dose
level for concomitant chemoradiation are listed in Table 4.
TABLE 2. Toxicities Associated with Induction
Chemotherapy
Toxicities, (n  36)
n (%)
Grade 1 Grade 2 Grade 3 Grade 4
Hematologic toxicities
Leukocytes 8 (22) 13 (36) 2 (6) 2 (6)
ANC 5 (14) 9 (25) 9 (25) 8 (22)
Hemoglobin 16 (44) 14 (39) 1 (3)
Platelets 10 (28) 1 (3)
Non-hematologic toxicities
Neutropenic
fever/infection
2 (6)
Non-neutropenia infection 2 (6)
Fatigue 22 (61) 7 (19)
Nausea 17 (47) 5 (14)
Vomiting 11 (31) 2 (6) 1 (3)
Diarrhea 17 (47) 6 (17) 1 (3)
Constipation 11 (31) 2 (6)
Neuropathy 6 (17) 1 (3)
Creatinine 1 (3)
Mucositis 2 (6)
Esophagitis 1 (3)
TABLE 3. Treatment Dose Levels and Dose Limiting Toxicities (DLT)
Dose Level n Irinotecan (I); Paclitaxel (P); Carboplatin (C) Median Radiation Dose (Range) No. of Patients with DLT
0 4 I 30 mg/m2; P 45 mg/m2 weekly; C AUC  2
weekly
6400 (5000–7000) 4
1 6 I 30 mg/m2 weekly; P 45 mg/m2 weekly; C 6533 (5000–7000) 3
2 10 I 30 mg/m2 weekly; P 40 mg/m2 weekly; C 6511 (5000–7400) 4
3 9 I 30 mg/m2 weeks 2, 3, 5, 6; P 40 mg/m2 weeks
2, 3, 5, 6; C
6500 (5940–7020) 1
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There were no grade 4 toxicities observed at any dose level.
At the dose level 3, the recommended phase II dose, no
grade 3 hematologic toxicities were observed. Grade 1/2
anemia, leucopenia, neutropenia, and thrombocytopenia oc-
curred in 89%, 33%, 22%, and 22% of the nine patients,
respectively. The only grade 3 nonhematologic toxicity was
esophagitis occurring in 11% of these patients. Among all 29
patients, nonhematologic grade 1/2 toxicities included the
following: fatigue (86%), nausea (48%), diarrhea (24%), and
vomiting (17%).
Response to Concomitant Chemoradiotherapy
Of the 29 patients who underwent chemoradiotherapy,
one patient (3%) was found to have brain metastasis at the
completion of therapy (Table 5). Partial responses were
attained in 16 (55%; 95% CI, 36–74%) patients whereas 12
patients (41%) attained disease stabilization.
Eleven patients were initially thought to be surgically
resectable, but only six patients underwent thoracotomy, of
which two patients had pathologic complete responses, two
had microscopic residual disease, and two had gross residual
disease. One of the patients who had brain metastasis at the
completion of therapy underwent thoracotomy for palliation
of chest wall pain.
Survival
The median length of follow-up for all 37 patients was
20.6 months (range 1.1–78.0). Twenty-five of the 37 eligible
patients have died. Among the 12 survivors, the median
length of follow-up was 68.3 months (range 35.0–78.0).
Median overall survival was 20.6 months (95% CI,
11.0–40.7 months) for the entire cohort (Figure 2A). The
median progression-free survival time was 7.6 months (95%
CI, 5.8–22.8 months) for the entire cohort (Figure 2B). For
patients deemed resectable at registration, median overall
survival was 24.4 months (95% CI, 1.9–). For patients
deemed unresectable, median overall survival was 18.8
months (95% CI, 10.9–40.7) (Figure 2C). Median progres-
sion-free survival for resectable patients was 13.7 months
(95% CI, 1.2–). The median progression-free survival time
for unresectable patients was 7.6 months (95% CI, 5.8–29.2)
(Figure 2D). The differences in overall and progression-free
survival rates between resectable and unresectable patients
were not statistically significant (p  0.52 and p  0.90,
respectively).
Pattern of Failure
As of the last follow up, 12 (32%) out of 37 patients
were alive. Ten patients were alive without evidence of
disease whereas seven had died without evidence of recur-
rence. Twenty patients (54%) out of the 37 developed disease
progression. Six of these patients (30%) experienced local
failure, 11 (55%) developed distant metastases, and three
patients (15%) developed disease recurrence locally and at
distant sites. Seven patients developed central nervous system
metastases as the site of first relapse.
Long-term Complications and Sequelae
Four out of the 29 patients (14%) who underwent
chemoradiotherapy developed an esophageal stricture and
required an esophageal dilation procedure on at least one
occasion. One patient developed a second primary lung
cancer outside the radiotherapy field, and another patient
developed a malignant thymoma.
DISCUSSION
The aim of the present investigation was to evaluate the
feasibility, toxicity, and safety of an intensive chemoradiother-
TABLE 4. Toxicities Associated with Concomitant Chemoradiotherapy
Grade
Dose Level 0 (n  4) Dose Level 1 (n  6) Dose Level 2 (n  10) Dose Level 3 (n  9)
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Hematologic toxicities
WBC 1 3 3 2 1 4 3 2 1
ANC 1 3 1 1 3 3 1 2 2
Hemoglobin 1 3 3 1 1 7 2 5 3
Platelets 2 3 2 2
Nonhematologic toxicities
Fatigue 3 3 3 8 1 7
Esophagitis 1 2 1 2 3 1 1 1 8 6 1
Nausea 2 4 4 3 1
Vomiting 1 2 2
Diarrhea 1 4 2
Pneumonitis 1 1 1 1
TABLE 5. Response Evaluation
Response to
Therapy n (%)
Surgical
Resection Pathologic Response
Partial response 16 (55) 4 1 no residual tumor
2 microscopic tumor deposits
1 gross tumor deposits
Stable disease 12 (41) 1 1 no residual tumor
Progressive disease 1 (3) 1a 1 gross tumor deposits
a Surgical resection was performed for palliation of chest wall pain.
Choong et al. Journal of Thoracic Oncology • Volume 3, Number 1, January 2008
Copyright © 2007 by the International Association for the Study of Lung Cancer64
apy protocol in patients with stage III NSCLC. Based on our
results, it was not feasible to administer carboplatin, paclitaxel,
and irinotecan concurrently with chest radiation therapy because
of dose-limiting neutropenia. The regimen was feasible only
after omission of carboplatin and reduction of doses to irinotecan
30 mg/m2 and paclitaxel 40mg/m2 delivered on weeks 2, 3, 5,
and 6 with concurrent daily chest radiotherapy.
This study was performed during a time when knowledge
of irinotecan metabolism by uridine diphosphoglucuronosyl-
transferase 1A1 polymorphism was still in its infancy.30 The
contribution of such polymorphisms to the toxicities observed in
our trial is unknown. One may hypothesize that the tolerability
of irinotecan may be better if patients were genotyped and dosed
accordingly. Regardless, the results of this phase I trial show that
the concurrent chemotherapy regimen of irinotecan, carboplatin,
and paclitaxel was poorly tolerated and was only feasible with
the omission of carboplatin and significant dose de-escalations.
Therefore, we do not recommended that this regimen be inves-
tigated further. Nevertheless, several important observations
need to be highlighted.
Firstly, despite significant dose de-escalations, the che-
moradiotherapy regimen utilizing for the most part irinotecan
and paclitaxel attained a long-term 5-year overall survival
rate of approximately 30% (95% CI, 17–46%). Even for
patients who were deemed unresectable at registration (n 
26), their 5-year survival was 25% (95% CI, 10–43%). These
survival figures seem similar to those achieved by other
established chemoradiotherapy regimens, but this comparison
must be made in light of our small number of patients and the
lack of statistical power. Furthermore, the contribution of the
triplet induction regimen to this survival improvement is
unclear. Secondly, there seems to be a trend toward better
survival in the surgically resectable patients. This observa-
tion, based on a small number of patients and not statistically
significant, is consistent with the current literature.31–35 Recently
however, the North American Intergroup Trialists showed that
surgical resection after chemoradiotherapy did not significantly
improve treatment outcome over chemoradiotherapy alone.36 In
addition, the approach of using induction chemotherapy fol-
lowed by surgical resection also did not improve overall survival
over chemotherapy followed by radiotherapy.37 Therefore, al-
though surgically resectable patients may have a better outcome,
the role of surgery after induction chemotherapy or chemora-
diotherapy is questionable.
FIGURE 2. A: Overall survival in all eligible patients, B: Progression-free survival in all eligible patients, C: Overall survival by
Resectability Status (resectable --- dashed line, unresectable — solid line) at time of diagnosis, D: Progression-free survival by
Resectability Status (resectable --- dashed line, unresectable — solid line) at time of diagnosis.
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Thirdly, the response rate after induction chemotherapy
with the triplet regimen was 26% (95% CI, 12–43%) in the
35 assessable patients. Compared with induction chemother-
apy with carboplatin-paclitaxel in CALGB 39801,6 with a
response rate was 31%, the efficacy of the triplet induction
regimen seems similar. This is paradoxical to what is known
in the metastatic setting, whereby a triplet regimen improves
response rates but not overall outcome.38 Finally, late esoph-
ageal toxicity, as opposed to acute esophageal toxicity is
relatively uncommon. In a review across several combined
modality Radiation Therapy Oncology Group trials, the late
esophageal toxicity rates with sequential chemotherapy and
radiotherapy was 2.2%, and almost doubled with the use of
induction chemotherapy followed concurrent chemoradio-
therapy (3.6%).39,40 The rate of late esophageal toxicity ob-
served in our patients is higher compared with these reports.
Nevertheless, it is unlikely that the chemotherapy regimen
was the cause of this because patients who developed the late
toxicities were in the lower dose levels.
An interesting feature of our trial is the inclusion of
patients who have poor-risk factors—greater than 10%
weight loss and PS 2. We accrued three patients with PS 2,
three patients with weight loss 10% and one patient with
both these poor-risk factors. Most chemoradiotherapy trials in
NSCLC have excluded patients with poor-risk factors. In
trials specifically evaluating this population of patients, the
carboplatin-etoposide with concurrent radiotherapy regimen
seems well tolerated.41,42 In our trial, four of these seven
patients completed the prescribed regimen. The other three
patients developed progressive disease after induction che-
motherapy and did not receive chemoradiotherapy. Neverthe-
less, it is important to note that the poor-risk factor patients
who completed their regimens were not in dose level 0 where
they would have received all three chemotherapies. Although
this concurrent chemoradiotherapy is feasible in poor-risk pa-
tients not all such patients are equivalent and the optimal
chemoradiotherapy approach for these patients remains to be
defined.
Because this trial was conceived in 1999, the manage-
ment of Stage III NSCLC has evolved. One significant
change occurred with the reporting of the CALGB 39801
study. This study randomized unresectable stage III NSCLC
patients to either immediate concomitant carboplatin/pacli-
taxel with radiotherapy or two cycles of induction chemo-
therapy with carboplatin and paclitaxel followed by identical
concomitant chemoradiation, and it found that the survival
outcomes between the two groups were no different.6 In light
of the CALGB 39801, concomitant chemoradiotherapy is
currently considered the standard approach for patients with
unresectable NSCLC and a good PS.3,4
A second major impact on the treatment of unresectable
stage III NSCLC came with the reporting of Southwest
Oncology Group (SWOG) 9504 and a subsequent random-
ized trial by the Hoosier Oncology Group. The use of con-
current chemoradiotherapy followed by consolidation chemo-
therapy, as pioneered by SWOG 901943 and later optimized
in SWOG 9504,2,44 has been adopted as a standard approach
for unresectable stage III NSCLC. The Hoosier Oncology Group
evaluated the role of consolidation chemotherapy and found that
there was no significant difference in survival between the group
that received consolidation docetaxel and those who did not.45
Therefore, concomitant chemoradiotherapy remains the standard
approach for unresectable stage III NSCLC.
Future investigations of multimodality management of
NSCLC should include novel targeted therapies, such as
tyrosine-kinase inhibitors. Nevertheless, the promise of tar-
geted therapies must be explored carefully and rationally
because the incorporation of such therapies may lead to
detrimental outcomes such as in SWOG 0023.46 As far as the
incorporation of irinotecan to chemoradiotherapy, we found
that a triplet chemoradiotherapy regimen was not feasible.
Nevertheless, even with several dose de-escalations, the iri-
notecan-based chemoradiotherapy for stage III NSCLC
seems efficacious. As the field of stage III NSCLC moves
forward, the role of irinotecan-based radiosensitizing-dose
chemoradiotherapy may be limited because the focus of
investigations has shifted to improving outcomes of full-dose
concurrent chemoradiotherapy with consolidation regimens.
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